诺华地拉罗司效果怎么样？

Novartis is the first oral iron anthelmintic approved by the U.S. FDA for routine use in patients ≥2 years of age with chronic iron overload caused by blood transfusions. Deferasirox is an oral active chelating agent that is highly selective for iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio.

How effective is Novartis deferasirox?

The clinical trial evaluates the efficacy and safety of Deferasirox (Deferasirox) produced by Novartis, Switzerland, in the treatment of iron overload in patients with β-thalassemia major (β-thalassaemia). 

Results: None of the 23 patients with severe β-thalassaemia used in the study group used iron chelators regularly before treatment, and their iron overload condition was severe [the average baseline value of serum ferritin was (5433.96±2873.90) μg/L].20 mg·kg-1·d-1 of deferasirox (Deferasirox) can maintain the patient's iron overload in a balanced state, and there is no significant change in serum ferritin levels before and after treatment; as the treatment time prolongs and the dosage increases, ≥30 mg·kg-1·d-1 of deferasirox (Deferasirox) can make patients' iron overload reach a negative balance state, and the difference in serum ferritin levels before and after treatment is statistically significant.

There were no serious adverse events during the study follow-up. Common adverse events were mild increases in liver transaminases and serum creatinine. All 23 patients were able to take the medicine on time and successfully completed the clinical study, with no deaths. Conclusion: As a new oral iron chelator, deferasirox (Enrige) can significantly improve patients' iron overload status.

Recommended related hot articles: /newsDetail/88623.html